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Abstract
Background: The United States (U.S.) Department of Veterans Affairs (VA) Quality Enhancement
Research Initiative (QUERI) has implemented economic analyses in single-site and multi-site clinical
trials. To date, no one has reviewed whether the QUERI Centers are taking an optimal approach
to doing so. Consistent with the continuous learning culture of the QUERI Program, this paper
provides such a reflection.
Methods: We present a case study of QUERI as an example of how economic considerations can
and should be integrated into implementation research within both single and multi-site studies.
We review theoretical and applied cost research in implementation studies outside and within VA.
We also present a critique of the use of economic research within the QUERI program.
Results: Economic evaluation is a key element of implementation research. QUERI has
contributed many developments in the field of implementation but has only recently begun multi-
site implementation trials across multiple regions within the national VA healthcare system. These
trials are unusual in their emphasis on developing detailed costs of implementation, as well as in the
use of business case analyses (budget impact analyses).
Conclusion: Economics appears to play an important role in QUERI implementation studies, only
after implementation has reached the stage of multi-site trials. Economic analysis could better
inform the choice of which clinical best practices to implement and the choice of implementation
interventions to employ. QUERI economics also would benefit from research on costing methods
and development of widely accepted international standards for implementation economics.
Background
Economic evaluation is essential to implementation
research. Reliable documentation of costs and outcomes
is necessary for healthcare managers to assess the success
of the implementation program as designed, to locate
potential avenues for cost-saving modifications, and to
judge the value of the implementation program relative to
other spending options.
The United States (U.S.) Department of Veterans Affairs
(VA) Quality Enhancement Research Initiative (QUERI)
has integrated economic analyses into almost every stage
of its development, starting from its inception in the late
1990s. Therefore, it provides a laboratory for testing
implementation research programs and methods in an
American context. QUERI Centers, the decentralized,
operational organization structure for the Program, have
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recently begun to carry out large-scale implementation
studies that feature substantial economic analyses. They
include cost-identification analyses, cost-effectiveness
analyses with and without utilities measurement, and, in
a few cases, a budget impact analysis. To date, no one has
reviewed whether the QUERI Centers are taking an opti-
mal approach to economic analyses. There are additional
and alternative methods for economic analysis, but it is
unclear a priori whether they are appropriate to the VA
institutional framework.
This paper presents a case study of QUERI as an example
of how economic considerations can and should be inte-
grated into the implementation research program of a
large, multi-region provider. It describes how economics
has been integrated into QUERI implementation pro-
grams, and how these methods comport with the institu-
tional structure of VA and its decision-making process. We
then assess the strengths and weaknesses of this approach
and suggest lessons that could apply to implementation
research in other health systems.
This article is one in a Series of articles documenting
implementation science frameworks and approaches
developed by the U.S. Department of Veterans Affairs
Quality Enhancement Research Initiative (QUERI).
QUERI is briefly outlined in Table 1 and is described in
more detail in previous publications [1,2]. The Series'
introductory article [3] highlights aspects of QUERI that
are related specifically to implementation science, and




There is general consensus about the appropriate methods
of conducting cost-utility analysis alongside traditional
clinical trials [4,5]. An advisory panel commissioned by
the U.S. Public Health Service defined a standard method
for U.S. researchers [5]. Known as the "reference case,"
this method prescribes that health care innovations be
compared to standard care, that all costs incurred by soci-
ety over a lifetime time-horizon be counted, and that out-
comes be valued in quality-adjusted life years (QALYs), a
measure of morbidity-adjusted survival.
Standards for cost-utility analysis and other forms of cost
analyses within implementation research have not been
adopted by an international professional association, or
by any federal agency in the U.S. One recourse is to
develop criteria for carrying out standard economic anal-
yses. The U.S. Public Health Service report noted above is
a widely accepted American reference. The British Medical
Journal (BMJ) uses 35 criteria to judge economic analyses
submitted for publication [6]. Both sources address many
major elements of economic analyses directly or by impli-
cation, although they do not feature elements unique to
implementation research.
Although a standard set of guidelines remains to be devel-
oped, individual elements of the design and economic
analysis of implementation projects have been published.
For example, McIntosh identified the stages of the imple-
mentation process and the costs and benefits associated
with each: development of the implementation strategy,
dissemination to managers and providers, implementa-
tion of the interventions, and the impact of each interven-
tion on patient and provider costs [7]. The four phases of
Severens' are similar [8]. The range of standard trial
Table 1: The VA Quality Enhancement Research Initiative (QUERI)
The U.S. Department of Veterans Affairs' (VA) Quality Enhancement Research Initiative (QUERI) was launched in 1998. QUERI was designed to 
harness VA's health services research expertise and resources in an ongoing system-wide effort to improve the performance of the VA healthcare 
system and, thus, quality of care for veterans.
QUERI researchers collaborate with VA policy and practice leaders, clinicians, and operations staff to implement appropriate evidence-based 
practices into routine clinical care. They work within distinct disease- or condition-specific QUERI Centers and utilize a standard six-step process:
1) Identify high-risk/high-volume diseases or problems.
2) Identify best practices.
3) Define existing practice patterns and outcomes across the VA and current variation from best practices.
4) Identify and implement interventions to promote best practices.
5) Document that best practices improve outcomes.
6) Document that outcomes are associated with improved health-related quality of life.
Within Step 4, QUERI implementation efforts generally follow a sequence of four phases to enable the refinement and spread of effective and 
sustainable implementation programs across multiple VA medical centers and clinics. The phases include:
1) Single site pilot,
2) Small scale, multi-site implementation trial,
3) Large scale, multi-region implementation trial, and
4) System-wide rollout.
Researchers employ additional QUERI frameworks and tools, as highlighted in this Series, to enhance achievement of each project's quality 
improvement and implementation science goals.
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designs was detailed by Eccles et al., including rand-
omized controlled trials (RCTs), before-after studies, and
time-series designs [9]. A third line of research has focused
on how to compare alternative methods of care. The chap-
ter by Severens, et al. lists the standard approaches from
clinical research, such as cost-minimization and cost-
effectiveness analyses, and notes how the measurement
level and unit differ across types [10]. McIntosh [7] dem-
onstrates a balance sheet approach that compares costs
and benefits side-by-side, a simple form of cost-conse-
quences analysis [10].
An extension to traditional cost-effectiveness formulas
was presented by Mason et al. [11]. They note that imple-
mentation interventions add cost to the best practice they
seek to promote. Using algebra, they argue that the cost-
effectiveness of the implementation program paired with
a clinical intervention – what they term policy cost-effective-
ness – will be less than that of the clinical intervention
alone. An implicit assumption is that the cost-effective-
ness of the clinical intervention will remain fixed as it is
implemented on a wider scale; in practice, it is unclear
whether this will be true.
A second extension is budget impact analysis, which in
QUERI is called business case analysis. It is a restricted ver-
sion of cost-benefit analysis that employs a short time-
frame and considers only the financial consequences on
the payer. The aim of budget impact analysis is to support
decision-making by showing the net impact of a new
intervention on the payer's budget. An international
research group recently proposed guidelines for the devel-
opment and presentation of these analyses [12]. Although
implementation research is not mentioned in the guide-
lines, the proposed methods are readily applicable there.
Researchers outside VA also have made important gains in
understanding the field of implementation. Most do not
make specific reference to cost. A key exception is the
implementation model developed by Greenhalgh and
others [13], in which costs enter as "slack resources," an
antecedent to innovation, and as "dedicated resources," a
marker of readiness for innovation and a factor in the
implementation process.
Applied research
A recent study reviewed hundreds of implementation
studies published from 1966–1998 that attempted to
bring physicians into compliance with treatment guide-
lines [14,15]. The authors note three stages at which costs
could be considered: guideline development, guideline
dissemination and implementation, and secondary effects
of provider behavior changes on treatment costs. Of the
235 studies that met their criteria for inclusion, only 63
reported any cost information. (None were from QUERI,
which had just begun in 1998.) The studies varied in the
type of analyses presented, including cost-effectiveness
analyses (17%), cost-consequences analyses (60%), and
simple identification of costs (22%). All were found to
have some deficiency in presentation or methods accord-
ing to the BMJ criteria. Many more implementation eval-
uations have been published since 1998, but to our
knowledge they have not been systematically reviewed.
The newer methods in implementation economic
research have not been widely used to date. The policy
effectiveness equations of Mason et al. are relatively new
and so have had limited opportunity for use by others
[11]. Budget impact analysis remains relatively uncom-
mon in the medical literature [16]. Its use in implementa-
tion research appears to be limited to programs that aim
to reduce employer health care costs through proven
health-promotion activities for employees, such as smok-
ing cessation [17,18].
Qualitative studies abound in implementation research. A
common approach is to discuss factors affecting the suc-
cess of an implementation program ("barriers and facili-
tators") and to distill "lessons learned" for later projects
[19-24]. Although they lack economic analyses, some
point to the role financing can play as a facilitator [20,21].
In the following sections we assess implementation eco-
nomics in the QUERI program, offer several critiques, and
then suggest areas where implementation science meth-
odology needs further discussion and development.
Implementation research in VA QUERI
Methods
Economic analyses have played an important role in
QUERI since its inception. Researchers with experience in
health economics were engaged in the creation of QUERI
in the late 1990s. Annual oversight on the progress and
plans of QUERI Centers comes from the QUERI Research
and Methodology Committee, which engaged an econo-
mist to provide reviews and advice on the economic anal-
yses within each Center [25]. The QUERI program funds
economic research projects on a regular basis as part of
larger implementation projects, and through stand-alone
pilot grants.
QUERI researchers have made a number of contributions
to implementation science methods [3]. They have
described how to use theory to guide implementation
practice [26], recast external facilitation as a true imple-
mentation intervention [27], championed the role of
formative evaluation [28], emphasized the utility of gap
analysis in choosing interventions to implement [29], and
published reviews of "lessons learned" from implementa-
tion efforts in VA [30,31].
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Of these, only Kochevar and Yano make specific reference
to costs [29]. They promote a tool for determining
whether to implement an intervention: i.e., an assessment
of the reasons behind the gap between actual and guide-
line-concordant practice through observation, systems
analysis, interviews, surveys, and data analysis. Termed
diagnosis/needs assessment (D/NA), this process stands
in contrast to "solution-driven" approaches that focus first
on implementation and rely on formative evaluation to
determine the role of contextual factors. The authors note
that D/NA itself requires data collection and time, and
hence carries both a direct cost and the opportunity cost
of studying rather than acting.
Applied research
Economic analyses have played an important role in iden-
tifying best practices for implementation (QUERI step 2;
Table 1) and documenting existing practice patterns (step
3). They have included using a literature review or meta-
analysis to assess the cost-effectiveness of a clinical inter-
vention [32] and developing a decision-analytic model to
characterize its cost-effectiveness [33-36].
Economic analyses are now beginning to occur in QUERI
steps 4–6 as well. Step 4 represents studies that implement
best practices via one of QUERI's sequence of four phases
(Table 1), including on regional or national scales, docu-
menting the extent to which clinical outcomes (step 5)
and health-related quality of life (step 6) improve as a
result. An economic analysis that measures costs and util-
ity will inherently cover both steps 4 and 6. Several QUERI
Centers have reached this latter stage of economic analysis
in the last few years. We will discuss three projects that
have been extended to the regional or national level: col-
laborative care for depression, HIV screening, and influ-
enza vaccination for veterans with spinal cord injury.
Collaborative depression care
The Mental Health QUERI Center is conducting a pro-
gram to implement the best practice of collaborative treat-
ment for depression. The TIDES project (Translating
Initiatives for Depression into Effective Solutions) imple-
mented the collaborative-care model at seven locations in
three regional networks [37]. This program was revised
using formative evaluation and was expanded into a larger
multi-region (Phase 3) version, labeled ReTIDES
(Expanding and Testing VA Collaborative Care Models for
Depression) [38]. This new program has been imple-
mented at the original seven sites plus additional clinics in
a fourth VA delivery network.
The primary economic study in TIDES was an analysis
relating changes in total VA costs to changes in depression
symptoms and health care utilization. Data were gathered
in the first 18 months of treatment for each patient. A total
of nine VA facilities in three regional networks agreed to
participate. Random assignment at the patient level was
inadvisable due to a high risk of contamination across
arms. Therefore, assignment was done at the facility (site)
level, with two intervention sites and one control site in
each region. An interim analysis at seven months indi-
cated significant improvement in the use of antidepres-
sants, without an increase in average cost per patient. A
final report is in preparation.
A unique aspect of the TIDES economic evaluation is care-
ful measurement of time spent on implementation-
related activities prior to kick-off of the clinical best prac-
tice intervention. In particular, researchers documented
the effort needed to disseminate earlier findings to leaders
at seven VA sites in an effort to win approval to carry out
the collaborative care intervention. Costs include time
spent in face-to-face meetings, training, telephone calls,
and writing and reading e-mail messages. Over two years
elapsed between initial contact and kick-off, on average;
research consultants, local and regional VA managers, and
clinical providers spent hundreds of hours on the project
per site [39].
The ReTIDES team also is developing a budget impact
(business case) analysis designed to provide VA managers
with the financial impact of adopting the collaborative
model. It employs the perspective of a VA manager at the
facility level, identifying new costs attributable to the pro-
gram, primarily the depression case managers, and the
extent to which these costs are offset by reductions in
other costs, such as primary care visits for depression and
depression-related somatic ailments, as well as reductions
in appointment no-shows. Costs and benefits solely expe-
rienced by patients, such as co-payments and utility
changes, enter the business case analysis only indirectly
through their correlation with changes in treatment type
and intensity. The budget impact analysis also examines
the effect of the ReTIDES program on the performance
measures for depression treatment that are used by VA to
evaluate managers.
HIV screening
A major focus of the HIV/Hepatitis-QUERI Center is to
improve screening rates for HIV. Rather than conduct a
randomized controlled trial, it developed a decision
model from trial results and other data sources (Step 2;
Table 1). Results indicated that it would be cost-effective
by standard criteria to increase HIV testing [40]. On this
basis, QUERI researchers developed an implementation
program to improve HIV testing rates [41]. It combines an
electronic clinical reminder, provider activation efforts,
and audit/feedback reporting. Following an initial imple-
mentation at three sites and a formative evaluation, a
Implementation Science 2008, 3:20 http://www.implementationscience.com/content/3/1/20
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modified intervention will be rolled out at five sites in
three regions [41].
Two types of economic analyses will be performed: a cost-
utility analysis and a budget impact analysis. The cost-util-
ity analysis of the initial implementation trial will follow
the 'reference case' methods of Gold et al. [5] and is aimed
at both academic and managerial audiences. Working
with a university collaborator, the researchers developed a
decision model that allows managers to input local costs,
staff time, HIV prevalence, and anticipated effect sizes.
This flexibility enables the user to enter values that he or
she finds credible and to carry out sensitivity analyses. The
study team is using the model to develop a budget impact
analysis populated with actual costs and outcomes from
the ongoing implementation programs noted above, in
order to develop presentations on the net costs of wider
HIV testing. Leaders of the HIV/Hepatitis-QUERI report
that providing likely costs and effects through the budget
impact analysis has already assisted in removing barriers
to implementing the screening program described above
and in opening discussion with additional VA regional
managers about implementing the programs in their facil-
ities [40].
Influenza vaccination
The VA system has a significant number of patients with
spinal cord injuries (SCI). These individuals face greater
difficulty than others in overcoming influenza [42], often
requiring repeated health care encounters. The SCI-
QUERI team determined that annual, routine influenza
vaccination was a clinical best practice, but vaccination
rates were low in VA (33% in fiscal year (FY) 2001) [43].
Their first major effort was to develop an implementation
program consisting of reminder letters and educational
materials for patients, and standing pharmacy orders and
an electronic clinical reminder for providers. The program
was rolled out at selected SCI treatment centers across the
VA system, while other SCI centers received only educa-
tional materials and reminders. The vaccination rate
among veterans with spinal cord injury rose in both
groups, but somewhat more at the centers receiving the
full intervention program [43]. Unlike the depression
management and HIV screening initiatives, the imple-
mentation program for influenza vaccination was
planned and carried out without a formal economic anal-
ysis.
Critique of QUERI
We now present a critique of the QUERI approach to eco-
nomics. The judgments are based on published materials,
as well as the authors' personal experiences as QUERI
researchers, as a QUERI Center executive committee
member [3], and as a participant in meetings of the
QUERI Research and Methodology Committee.
Identifying a best practice (step 2)
QUERI researchers have used literature reviews and deci-
sion-analytic models to estimate the cost-effectiveness of
clinical interventions that are candidates for implementa-
tion. They also have developed and tested new interven-
tions, assessing costs and outcomes within clinical trials.
These are all appropriate methods, but there is room for
improvement in applying these methods more uniformly.
It appears that cost and cost-effectiveness are rarely dis-
cussed openly in choosing a clinical best practice to imple-
ment. The discussions do show, however, that an
intervention seen as "too expensive" will not move for-
ward without considerable evidence of support from VA
managers. This fits the observation of Neumann that CEA
(cost-effectiveness analysis) is used in the United States
"not as an explicit instrument for prioritizing health serv-
ices, but as a subtle influence in policy discourse" [[44], p.
309].
Implementation (steps 4–6)
There are several avenues through which economic analy-
sis can improve the implementation trial process (QUERI
steps 4–6). This section reviews three approaches: cost-
effectiveness analysis, formative evaluation, and budget
impact analysis. It ends with our assessment of barriers to
the greater use of these methods.
Cost-effectiveness analysis
The choice of implementation interventions could be
strengthened through the use of cost and cost-effective-
ness data. Decision modeling using clinical knowledge
and the results of published studies, and with proper sen-
sitivity analyses, would help to predict likely gains from
implementation [11,45,46]. Such calculations appear not
to be the norm in QUERI. A laudable exception is the
HIV/Hepatitis-QUERI's decision model on widespread
HIV testing that explicitly determined the minimum infec-
tion rate under which widespread testing would meet con-
ventional cost-effectiveness standards [35].
These calculations could, in turn, guide the choice of
implementation interventions, sometimes called "tools."
For example, Figure 1 of Sales et al. presents a schematic
model for employing theories of behavior change to guide
the choice of implementation tools (see [26]). The figure
could be modified by adding the text in italics: "Identify
tools for the intervention that fit both strategy and theory
and which lead to estimated cost-effectiveness acceptable to the
funder."
The QUERI Implementation Guide [47] suggests that
costs do not need to be measured when interventions are
tested at a single site, but only when a multi-site imple-
mentation trial has begun. We believe that measuring
costs at the single-site phase is advisable and could help to
Implementation Science 2008, 3:20 http://www.implementationscience.com/content/3/1/20
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refine the intervention prior to implementation at multi-
ple sites. Therefore, we recommend revision of the guide-
lines to add cost as a domain of measurement in single-
site studies.
In the case of using VA informatics innovations to
enhance adoption of best practices, the cost is so low that
there is often little need to formally estimate implementa-
tion intervention costs. The clinical reminder for influ-
enza vaccination is a case in point. The implementation
intervention consisted of developing and installing pro-
gramming code, and then electronically activating the
clinical reminder at each site. Once the initial code was
developed and installed, the site-level cost for mainte-
nance and the time spent by providers to read the remind-
ers were both minimal. (Whether development costs
should be considered at all is a matter of debate; Luce et
al. argue that the decision depends on the purpose of the
analysis and its perspective [48].) On the other hand, a
cost-effectiveness analysis may be necessary in order to
rank informatics innovations relative to other possible
uses of the same funds.
Aside from the informatics intervention noted earlier, the
only combination of a clinical best-practice and imple-
mentation program that has been rolled out at a regional
level is TIDES/ReTIDES in the Mental Health QUERI. The
two related programs have been exemplary in the range of
their data collection, covering clinical outcomes, cost and
quality of life.
Formative evaluation
A second avenue for judging the impact of costs and cost-
effectiveness is formative evaluation, a process strongly
encouraged by QUERI leaders throughout the implemen-
tation effort [28]. If a poor cost-effectiveness ratio or high
initial cost outlays are perceived as a barrier to implemen-
tation, the formative evaluation will bring this to light.
Summaries of formative evaluations have been published
as "lessons learned" articles from QUERI researchers
[30,31] and others [24]. Nevertheless, this tool appears to
be underutilized in QUERI research relative to cost analy-
sis.
Budget impact analysis
A third approach to assessing costs and benefits in Stage 4
is the budget impact analysis. We see it as a useful adjunct
to standard cost-effectiveness analyses. Health care man-
agers in many organizations have made clear that short-
term budget implications play an important role in deter-
mining whether a clinical intervention and associated
implementation intervention are approved [49,50].
Moreover, VA clinical leaders have often expressed skepti-
cism about claims of cost-offsets presented by clinical
researchers. A budget impact analysis that allows the user
to carry out sensitivity analyses, such as the model being
prepared by the HIV/Hepatitis-QUERI, will help to
address this skepticism.
Researchers have offered two major normative critiques of
the budget impact analyses. In essence they reflect the rea-
soning that led to the development of the reference case
CEA. First, a short-time horizon discounts the value of
programs that achieve health improvement only over the
longer term, such as smoking cessation. Second, making
decisions solely on the basis of a budget impact analysis
could lead to a socially worse set of health programs if it
persuaded managers to adopt a program that caused more
loss to patients than gain to the provider.
Both of these concerns may be assuaged by understanding
the place of the budget impact analysis in decision-mak-
ing. Several surveys have found that cost is just one of sev-
eral factors considered in making health care decisions;
scientific evidence of clinical improvement also is essen-
tial, and political support or opposition, particularly in
the U.S., can loom large [24,44,51]. There is no reason to
expect that cost will be the sole, or even primary driver.
Second, health care managers often have clinical training
that well acquaints them with the long-term benefits of
disease-prevention measures such as smoking cessation.
This recognition, however, does not alter the fact that they
face short horizons for budgeting. Indeed, the short-term
nature of decision-making has been named by health care
administrators as a barrier to using traditional health-eco-
nomic studies [4,44,49].
A technical critique is that budget impact analysis could
result in a different decision than would a cost-utility
analysis (CUA). In reality, this is no problem at all
because the two address different questions. CUA alone
does not provide enough information – managers need to
know the total cost to determine whether implementation
is feasible given current resource constraints. Most CUAs
state an incremental cost-effectiveness ratio (ICER) of one
treatment relative to another, expressed as dollars per
quality-adjusted life year ($/QALY). Although many
researchers refer to certain ICER levels as dividing cost-
effective from not cost-effective, there is no threshold for
budget impact analysis that divides "acceptable" from
"not acceptable." The distinction between negative and
positive net cost is an appealing divide, but it is purely
arbitrary.
We believe that the fundamental unease with budget
impact analysis comes from a fear that an implementation
intervention found to be cost-effective through a CUA will
be rejected if a budget impact analysis reveals high initial
costs without quick gains in clinical outcomes. However,
in our experience with VA senior managers we have found
Implementation Science 2008, 3:20 http://www.implementationscience.com/content/3/1/20
Page 7 of 9
(page number not for citation purposes)
that they are keen to know both budgetary impacts and
cost-effectiveness. If cost data are not provided, they may
assume a worst-case scenario that overstates actual costs.
Moreover, there is no reason to believe that managers will
automatically disregard any intervention with a positive
short-term cost. In VA, for example, the widespread avail-
ability of outpatient smoking-cessation clinics implies
that the agency takes a long-run view.
We do not advocate for the exclusive use of budget impact
analyses. Rather, economic analyses should serve the
needs of health care decision-makers, one of which is a
defensible estimate of the provider's costs over a relatively
short timeframe. Budget impact analysis is insufficient as
a stand-alone method, but provides a key additional ben-
efit to the most important consumers of these economic
analyses: the managers who are highly influential in
deciding whether to implement a clinical best-practice
and its associated implementation intervention. If budget
impact analysis finds a low-net cost up front, they will be
more likely to approve an implementation scheme, even
if its incremental cost-effectiveness ratio is relatively high.
Barriers to economic analysis
Although QUERI Centers have produced nearly two-
dozen cost-related publications, much more could be
done. Our review of QUERI publications shows that rela-
tively few refer to costs at all, and, of those that do, many
are decision models rather than results of clinical trials at
VA. QUERI studies often refer to utilization and health-
related quality of life without going a step further and
measuring costs. When QUERI began in the late 1990s,
this may have reflected the historical lack of accurate
encounter-level data. Now, most QUERI studies refer to
clinical events since 2000 – a period during which two
separate and reliable cost data sets have been available
[52].
We see several obstacles to greater economic evaluation in
QUERI. The first is knowledge: clinical researchers are
familiar with clinical outcomes, whereas cost and utility
are often new concepts. A second is habit. Health eco-
nomic analyses were relatively rare prior to the 1990s;
researchers trained before then would not have learned,
early on, to integrate cost analyses into their work. A third
is the lack of expert-panel recommendations for imple-
mentation research economics. There are many resources
for planning a cost-effectiveness analysis of clinical inter-
ventions, but relatively few for the cost and cost-effective-
ness of implementation interventions. Expert
recommendations will not be followed by all researchers,
of course, but without them there is little basis beyond
personal experience for proposing cost analyses – or for
reviewing proposals on behalf of funding agencies. A
fourth is VA funding limits. VA researchers sometimes
treat economic analysis as an adjunct that can be dropped
when funds are tight, leading to many missed opportuni-
ties to gather economic data during the pre-implementa-
tion phase.
Conclusion
Our review of QUERI economic research has revealed
strengths in some areas but considerable room for growth.
QUERI researchers have made notable contributions to
the qualitative methods of implementation research, and
several QUERI Centers are exemplary in incorporating a
variety of economic evaluations into multi-site imple-
mentation projects. Other Centers, however, have missed
opportunities to study the costs of the interventions they
are testing and do not appear to use economic data explic-
itly when choosing a best-practice intervention to imple-
ment. One solution is to institute processes for sharing
methodological knowledge to researchers elsewhere in
the system. Within VA, this is accomplished, in part,
through agency-sponsored conferences, but it appears
that more needs to be done.
QUERI economists also could contribute to general meth-
ods of implementation economics. For example, we
believe further discussion is needed on development and
dissemination costs. Luce et al. argued more than 10 years
ago that such costs could be included or excluded depend-
ing on the perspective and the decision the analysis
addresses [48]. More recently, however, several others
have included development costs without comment on
whether they should ever be excluded [8,10,43]. The issue
is particularly important in implementation research
because the process of formative evaluation often leads to
additional development costs at each stage of implemen-
tation. As well, the review by Vale et al. shows that many
implementation programs employ multiple implementa-
tion interventions [15], thereby adding additional com-
plexity to the calculation of development costs.
Dissemination costs also raise important questions. For
example, should one count the cost of meetings, tele-
phone calls, and e-mails as the implementation interven-
tion is broached with managers at a new site? This
approach has been taken by the Mental Health QUERI
Center in the ReTIDES project. Several recent authors have
noted the importance of counting dissemination costs,
but the examples given relate to contacts with clinical staff
once a decision has been made to carry out the interven-
tion [7,8,46]. Another question is how to treat time spent
in discussion with national- and regional-level VA manag-
ers who may have considerable sway over the decision to
begin an implementation trial at a particular VA facility.
The effort needed to collect such data is non-trivial. Once
enough implementation projects have occurred in VA, it
may be possible to develop estimates of the average cost
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of engagement with VA managers in place of the labor-
intensive micro-costing approach.
We believe the QUERI experience illustrates several points
that apply more generally to implementation in large
health systems. First, it is feasible to incorporate econom-
ics at every phase of implementation. A key element is a
sustained philosophical and financial commitment to
economic research from senior managers. Second, there is
path dependence in economic research: Centers with
experience in economic research tend to continue incor-
porating it into ever larger research agendas, while those
having little acquaintance with economics seem slow to
take it up. Increasing the use of economic research may
require surveys of implementation researchers them-
selves, in order to learn the barriers they perceive. For
example, within VA a survey of QUERI researchers indi-
cated that many were interested in economics training but
were unaware that such training was already available.
Finally, we would highlight the importance of developing
economic analyses that meet the needs of health care
managers. An important initial step is to determine what
types of analyses will be useful in decision-making
between alterative implementation programs. Within VA,
this includes both cost-utility and budget impact analyses;
in other systems, a different or larger set of analyses may
be indicated.
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